Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lexicon Pharmaceuticals reports strong Q4 performance and eyes growth

Lexicon Pharmaceuticals showcased promising drug candidates and financial stability in Q4 2022.
While facing challenges in revenue generation and expense management, the company is strategically positioned for growth.
Opportunities lie in commercial launches, Phase 3 advancements, and potential partnerships to drive future success.
Overall, Lexicon's focus on maximizing asset value and advancing key drugs positions them for long-term success in the pharmaceutical market.

Lexicon Pharmaceuticals reports robust Q1 performance and eyes market expansion

Lexicon Pharmaceuticals showcased strong financials, promising drug candidates, and strategic confidence in market success.
Challenges lie in market penetration strategies, FDA feedback, and successful commercialization amidst competition.
Opportunities abound with upcoming sotagliflozin launch, advancing LX9211, and leveraging unique data for growth.

Lexicon Pharmaceuticals reports strong Q2 earnings and advances key treatments

Lexicon Pharmaceuticals demonstrated financial stability and strategic progress in Q2 2023, supported by strong cash reserves and key regulatory milestones.
The company's focus on patient-centric initiatives and upcoming product launches positions it for sustained growth and market success.
Challenges in market penetration and revenue realization require targeted strategies, while opportunities in market expansion and pipeline development offer avenues for growth.
Overall, Lexicon Pharmaceuticals shows promise with a solid foundation for future success, driven by innovation and market-focused strategies.

Lexicon Pharmaceuticals reports Q3 loss, highlights INPEFA progress and global expansion

Lexicon Pharmaceuticals faces challenges in market access and inventory trends while capitalizing on opportunities through geographic expansion and potential partnerships. The company's financial performance in Q3 2023 showed increased expenses but progress in prescription demand for INPEFA.

Lexicon Pharmaceuticals reports strong Q1 performance and growth opportunities

Lexicon Pharmaceuticals showcased strong performance and progress in Q1 2024, with a focus on product launches and market access.
Despite challenges in achieving full access and addressing specific patient needs, the company remains optimistic about future growth opportunities.
Positive customer feedback, ongoing pipeline advancements, and strategic market considerations position Lexicon well for future success and sales acceleration.

Lexicon Pharmaceuticals reports Q3 progress amidst financial challenges and opportunities

Lexicon Pharmaceuticals showcased progress in key development programs and strategic partnerships in Q3 2024.
Despite financial challenges, the company's operational strengths and focus on growth opportunities are notable.
Navigating uncertainties around ZYNQUISTA and competition in the market are key challenges ahead.
Overall, the company's performance, strengths, challenges, and opportunities shape its strategic outlook for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lexicon (LXRX) delivered earnings and revenue surprises of -144.44% and -60.73%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Cooper Tire & Rubber

Insperity

Earnings and other woes weighed on these stocks.

Why Cooper Tire & Rubber, Insperity, and Lexicon Pharmaceuticals Slumped Today

Sanofi is walking away from an important collaboration, leaving shareholders wondering what's next.

Here's Why Lexicon Pharmaceuticals Is Collapsing Today

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares were absolutely crushed on Monday after it was announced that Sanofi would be ending its partnership with the firm.

Is This Lexicon Pharmaceuticals Panic Overblown?

Shares of Lexicon Pharmaceuticals Inc. LXRX, +1.43% lost more than half their value (down 53.4%) toward a record low in active premarket trading Monday, after the drug maker said Sanofi SNY, +0.79% wanted to end the alliance around its diabetes treatment Zynquista.

Lexicon's stock loses more than half its value after Sanofi's notice to end alliance

Lexicon Pharmaceuticals (NASDAQ: LXRX) shares plummeted after the company received a written notice from Sanofi (NASDAQ: SNY) terminating the agreement for the development and commercialization of the company's Diabetes drug candidate Sotagliflozin.

Lexicon Shares Fall 47% On Termination Of License Agreement With Sanofi

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2019 Results - Earnings Call Transcript

Will Lexicon Pharmaceuticals (LXRX) Report Negative Q1 Earnings? What You Should Know

FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.

Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug

American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.

What's Next for Lexicon Pharmaceuticals?

Finally, shares of Lexicon Pharmaceuticals plunged 22%.

Why Lexicon Pharmaceuticals Slumped Today

Amarin Corporation Plc

AstraZeneca

Jazz Pharmaceuticals

Ligand Pharmaceuticals

Leap Therapeutics

PhaseBio Pharmaceuticals Inc

Roche Holding AG

SAGE Therapeutics

Strongbridge Biopharma

Sanofi

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

News for Lexicon Pharmaceuticals Stock (LXRX)